Author

R. Upstill-Goddard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:differential expression· 1

Frequent Co-Authors

U.-M. Bailey· 2 shared A. Ashworth· 1 shared A. Biankin· 1 shared A. D. Campbell· 1 shared A. DeFazio· 1 shared A. Gulati· 1 shared A. Johns· 1 shared A. K. Najumudeen· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

U.-M. Bailey

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity

S. K. Fey, A. K. Najumudeen, C. A. Ford, K. Gilroy, R. Upstill-Goddard, W. Clark, C. Nixon, D. K. Chang, S. T. Barry, J. P. Morton, A. D. Campbell, O. J. Sansom

This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.

bioRxiv · Aug 29, 2023 · PreprintCancer Biology

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

G. Y. Ho, E. Kyran, J. Bedo, M. Wakefield, D. Ennis, H. Mirza, S. Cooke, E. Lieschke, C. Vandenberg, O. Kondrashova, R. Upstill-Goddard, U.-M. Bailey, S. Biankin, P. Roxburgh, R. Glasspool, , H. Barker

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology

Targeting DNA damage response and Replication Stress in Pancreatic Cancer

S. Dreyer, R. Upstill-Goddard, V. Paulus-Hock, C. Paris, E. Maria-Lampraki, E. Dray, B. Serrels, S. Rebus, H. Brunton, C. Nourse, U.-M. Bailey, M. Jones, K. Moran-Jones, D. Wright, F. Duthie, , Lord

The paper identifies novel therapeutic strategies for pancreatic cancer by analyzing DNA damage response and replication stress in patient-derived cell lines.

bioRxiv · Jul 24, 2019Cancer Biology